The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into ...

Panelists discuss how the PERSEUS trial demonstrated superior progression-free survival with daratumumab-VRd compared to VRd alone in patients with transplant-eligible newly diagnosed multiple myeloma ...

Panelists discuss how to navigate and choose among multiple guideline-recommended induction regimens for patients with ...

Learn more about whether AbbVie Inc. or Genmab A/S is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...